Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.62 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465707 | 0.88 | NOTUM (0.63) | CHRNA7OPRL1NOTUMCNR1CNR2 | |
| SCHEMBL4492901 | 0.83 | MAPK1 (0.67) | CHRNA7OPRL1CNR1CNR2ALDH1A1 | |
| SCHEMBL5922313 | 0.82 | CHRNA7 (0.56) | CHRNA7NOTUMALDH1A1 | |
| SCHEMBL5922354 | 0.81 | CHRNA7 (0.61) | CHRNA7OPRL1CNR1CNR2 | |
| SCHEMBL5922302 | 0.80 | MAPT (0.63) | CHRNA7OPRL1NOTUMCNR1CNR2 | |
| SCHEMBL5922340 | 0.79 | CHRNA7 (0.54) | CHRNA7NOTUMCNR1CNR2ALDH1A1 | |
| SCHEMBL28017620 | 0.79 | NOTUM (0.74) | NOTUMALDH1A1 | |
| SCHEMBL5922332 | 0.78 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL4918783 | 0.77 | MAPK1 (0.60) | CHRNA7OPRL1CNR1CNR2ALDH1A1 | |
| SCHEMBL4484123 | 0.76 | NOTUM (0.54) | CHRNA7NOTUMCNR1CNR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524971-B2 | 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics | SANOFI - AVENTIS (FR) | 2009-04-28 | — | — | US | disclosed |
| US-20080015245-A1 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1853557-A2 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087476-A2 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015245-A1 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | QDPR, DPYD, CD38 | CHRNA7 3779/4885OPRL1 1286/4885NOTUM 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.